Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Unmet needs of patients with leiomyosarcoma

Brian Van Tine • 4 Jun 2022
ASCO 2022
Sarcoma

Brian Van Tine, MD, PhD, Washington University School of Medicine in St.Louis, St Louis, MO, talks on the need for a treatment with a low toxicity profile and significant durability for patients with leiomyosarcoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Brian Van Tine

0:54
What does the future hold for CAR T-cells in sarcoma management?
Brian Van Tine • 4 Jun 2023
0:33
Predicative biomarkers of response to immunotherapy in STS
Brian Van Tine • 4 Jun 2023
0:50
SPEARHEAD-1: afamitresgene autoleucel in advanced synovial sarcoma
Brian Van Tine • 4 Jun 2023
0:57
Cabozantinib with checkpoint inhibition in soft tissue sarcoma
Brian Van Tine • 4 Jun 2023

Related Videos

0:51
Enhanced NK-cells in stage 4 sarcoma treatment
Vaishali Kumar • 8 Apr 2024
1:12
Predictive biomarkers for checkpoint inhibitors in sarcomas
Nadia Omelchenko • 8 Apr 2024
1:26
SAINT and LINNOVATE: combining ICIs and chemotherapy in advanced STC
Nadia Omelchenko • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals